Ilsa Coleman

Distribution of KLK2 and STEAP1 single cell mRNA expression in cells from ARPC samples across MSK scRNA dataset.

Supplementary Figure 6 shows representative KLK2 and STEAP1 IHC micrographs with the H-score threshold of 20.

IHC H-scores of UW-RA samples, including phenotypes as defined by IHC.

Supplementary Figure 4 shows representative KLK2 IHC micrographs of LuCaP PDX tumors across phenotypes.

Supplementary Figure 9 contains donut plots showing the distribution of tumor expressing only one marker, both markers or neither marker for each KLK2-STEAP1, STEAP1-PSMA, and KLK2-PSMA pair across molecular phenotypes and across H-score thresholds.

Cell surface targets and their associated limma values from KLK2-high vs KLK2-low and STEAP1-high vs STEAP1-low differential expression analyses.

Results from predictive model integrating somatic alterations and serum PSA to estimate the probability that a sample is positive for the given antigen.

Supplementary Figure 3 shows KLK2 and STEAP1 expression in LuCaP PDX samples.

Tier 1 druggable genome targets and their associated limma values from KLK2-high vs KLK2-low and STEAP1-high vs STEAP1-low differential expression analyses.

Log2(TPM+1) values in SU2C-IDT samples, including phenotypes as defined by RNA-seq.